Biological and Pharmaceutical Bulletin · 2019 · 17 citations · 35 references
MedicinePharmacologyPharmacotherapyInflammationNeuroendocrinologyNeuropharmacologyAdrenal Axis RegulationAdrenal HormonesAdrenal Steroid HormonesBlood Pressure ManagementBlood Pressure RegulationHypertension PharmacotherapyAngiotensin Ii TherapyAntihypertensive PharmacologyBlood PressureCerebral Vascular ReactivityProinflammatory MediatorsVascular Damage ControlVascular Risk ManagementVascular Risk Reduction
The main objective of treatment against hypertension is not only to reduce blood pressure levels, but also to reduce vascular risk in general. In the present work, administering angiotensin II (AGII; 0.2 µg/kg intraperitoneally (i.p.) for 12 weeks) activates the hypothalamic-pituitary-adrenal (HPA) axis, which caused an increase in corticosterone levels, as well as in proinflammatory cytokines (interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α)) and macrophage chemotactic protein 1 (MCP-1), and decreased anti-inflammatory cytokines (interleukin 10 (IL-10) and interleukin 4 (IL-4)). On observing the behavior in the different models, an anxiogenic effect (elevated plus maze (EPM)) and cognitive impairment (water Morris maze (WMM)) was observed in animals with AGII. By administering organic extracts from Ocimum basilicum (Oba-EtOAc) and Ocimum selloi (Ose-EtOAc), and some doses of rosmarinic acid (RA) (6 weeks per os (p.o.)), the damage caused by AGII was stopped by re-establishing corticosterone serum levels and by decreasing the proinflammatory cytokines and MCP-1.
35
Munekazu Komada, Keizo Takao, Tsuyoshi Miyakawa · Journal of Visualized Experiments · 2008 · 526 citations · Full text